Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices

Journal of Heart and Lung Transplantation

Volumn 36, Issue 4, 2017, Pages 380-385

  Houston, Brian A ^a   Schneider, Andrea L C ^b   Vaishnav, Joban ^c   Cromwell, David M ^b   Miller, P Elliott ^c   Faridi, Kamil F ^c   Shah, Ashish ^d   Sciortino, Chris ^b   Whitman, Glenn ^b   Tedford, Ryan J ^b   Stevens, Gerin R ^b   Judge, Daniel P ^b   Russell, Stuart D ^b   Rouf, Rosanne ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitor; ARB; Arteriovenous malformations; GI bleed; LVAD

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ADULT; ARTERIOVENOUS MALFORMATION; ARTICLE; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PRIORITY JOURNAL; RISK REDUCTION; AGED; COMPLICATION; HEART ASSIST DEVICE; HEART FAILURE; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOVENOUS MALFORMATIONS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 85011389251     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2016.12.016     Document Type: Article

References (38)

1. 1 Go, A.S., Mozaffarian, D., Roger, V.L., et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 127 (2013), 143–152.
2. 2 Stewart, G.C., Stevenson, L.W., Keeping left ventricular assist device acceleration on track. Circulation 123 (2011), 1559–1568.
3. 3 Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant 33 (2014), 555–564.
4. 4 Rose, E.A., Gelijins, A.C., Moskowitz, A.J., et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 (2001), 1435–1443.
5. 5 Rogers, J.G., Butler, J., Lansman, S.L., et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 50 (2007), 741–747.
6. 6 Jorde, U.P., Kushwaha, S.S., Tatooles, A.J., et al. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 63 (2014), 1751–1757.
7. 7 Morgan, J.A., Paone, G., Nemeh, H.W., et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant 31 (2012), 715–718.
8. 8 Stern, D.R., Kazam, J., Edwards, P., et al. Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg 25 (2012), 352–356.
9. 9 Crow, S., John, R., Boyle, A., et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 137 (2009), 208–215.
10. 10 Lestou, G.V., Shah, N., Gregoric, I.D., Myers, T.J., Delgado, R., Frazier, O.H., GI bleeding from arterio-venous malformations in patients supported by the Jarvik 2000 axial flow left ventricular assist device. J Heart Lung Transplant 24 (2005), 105–109.
11. 11 Uriel, N., Pak, S.W., Jorde, U.P., et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 56 (2012), 1207–1213.
12. 12 John, R., Kamdar, F., Eckman, P., et al. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. Ann Thorac Surg 92 (2011), 1593–1599.
13. 13 Aggarwal, A., Pant, R., Kumar, S., et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thoracic Surg 93 (2012), 1534–1540.
14. 14 Estep, J.D., Starling, R.C., Horstmanshof, D.A., et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol 66 (2015), 1747–1761.
15. 15 Demirozu, Z.T., Radovancevic, R., Hochman, L.F., et al. Arteriovenous malformations and gastrointestinal bleeding in patients with HeartMate II left ventricular assist device. J Heart Lung Transplant 30 (2011), 849–853.
16. 16 Junquera, F., Saperas, E., de Torres, I., Vidal, M.T., Malagelada, J.R., Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 94 (1999), 1070–1076.
17. 17 Fujita, H., Momoi, M., Chuganji, Y., Tomiyama, J., Increased plasma vascular endothelial growth factor levels in patients with angiodysplasia. J Intern Med 248 (2000), 268–269.
18. 18 Ahamed J, Monteagudo J, Kinkhabwala M, et al. Patients with end stage congestive heart failure have decreased high molecular weight von Willebrand factor multimers and higher plasma levels of total TGF-β1: implantation of a left ventricular assist devices (LVAD) exacerbates both abnormalities. Oral and poster abstracts presented at: 55th Annual American Society of Hematology Meeting and Exposition. December 7-13, 2013; New Orleans, Louisiana.
19. 19 Welp, H., Rukosujew, A., Tjan, T.D., et al. Effect of pulsatile and non-pulsatile left ventricular assist devices on the renin-angiotensin system in patients with end-stage heart failure. Thorac Cardiovasc Surg 58:suppl 2 (2010), S185–S188.
20. 20 Shao, E.S., Lin, L., Yao, Y., Boström, K.I., Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114 (2009), 2197–2206.
21. 21 Ferrari, G., Cook, B.D., Terushkin, V., Pintucci, G., Mignatti, P., Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 219 (2009), 449–458.
22. 22 Bertolino, P., Deckers, M., Lebrin, F., ten Dijke, P., Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 128:6 suppl (2005), 585S–590SS.
23. 23 Lim, D.S., Lutucuta, S., Bachireddy, P., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103 (2001), 789–791.
24. 24 Lavoie, P., Robitaille, G., Agharazii, M., Ledbetter, S., Lebel, M., Larivière, R., Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 23 (2005), 1895–1903.
25. 25 Brooke, B.S., Habashi, J.P., Judge, D.P., Patel, N., Loeys, B., Dietz, H.C. 3rd, Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 358 (2008), 2787–2795.
26. 26 Braverman, A.C., Transforming growth factor-β: a biomarker in Marfan syndrome. Circulation 120 (2009), 464–466.
27. 27 Shin, G.T., Kim, S.J., Ma, K.A., Kim, H.S., Kim, D., ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. Am J Kidney Dis 36 (2000), 894–902.
28. 28 Langham, R.G., Kelly, D.J., Gow, R.M., et al. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care 29 (2006), 2670–2675.
29. 29 el-Agroudy, A.E., Hassan, N.A., Foda, M.A., et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 23 (2003), 300–306.
30. 30 Yoshiji, H., Kuriyama, S., Fukui, H., Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23 (2002), 348–356.
31. 31 Otani, A., Takagi, H., Oh, H., Koyama, S., Honda, Y., Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes 50 (2001), 867–875.
32. 32 Stulak, J.M., Lee, D., Haft, J.W., et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant 33 (2014), 60–64.
33. 33 Wever-Pinzon, O., Selzman, C.H., Drakos, S.G., et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 6 (2013), 517–526.
34. 34 Loyaga-Rendon, R.Y., Hashim, T., Tallaj, J.A., et al. Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices. ASAIO J 61 (2015), 107–109.
35. 35 Draper, K., Kale, P., Martin, B., Cordero, K., Ha, R., Banerjee, D., Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant 34 (2015), 132–134.
36. 36 Tabit, C.E., Chen, P., Kim, G.H., et al. Elevated angiopoietin-2 level in patients with continuous-flow left ventricular assist devices leads to altered angiogenesis and is associated with higher nonsurgical bleeding. Circulation 134 (2016), 141–152.
37. 37 Rommel, J.J., O'Neill, T.J., Lishmanov, A., Katz, J.N., Chang, P.P., The role of heart failure pharmacotherapy after left ventricular assist device support. Heart Fail Clin 10 (2014), 653–660.
38. 38 Jennings, D.L., Jones, M.C., Lanfear, D.E., Assessment of the heart failure pharmacotherapy of patients with continuous flow left-ventricular assist devices. Int J Artif Organs 35 (2012), 177–179.